DyNAbind and Galapagos enter framework agreement
and Galapagos NV, a leading biotech company active in clinical stage drug discovery
and development, have entered a framework collaboration agreement for compound
screening based on DyNAbind’s proprietary DNA-Encoded Library (DEL)
technologies. This new longterm partnership aims at discovering novel drug
candidates for various indications, including inflammation and fibrosis.
Michael Thompson, Ph.D, co-founder and CEO of DyNAbind, explains the
importance of this deal: “There’s nothing more exciting for us at DyNAbind than using
our DEL technologies to help our partners create new medicines, so we’re thrilled
about signing this new long-term collaboration with one of the world leaders in drug
development. We are very much looking forward to working together with Galapagos’
R&D teams, and to join forces to contribute to their portfolio of clinical-stage first-in-
Financial terms of the collaboration agreement were not disclosed.
Galapagos is a pioneering biotechnology company, aiming to develop innovative
medicines to improve patients’ lives. Leveraging our proprietary target discovery
engine, we transform drug discovery and develop candidate medicines addressing
the root causes of disease. Our deep pipeline currently comprises more than 30
novel inflammation and fibrosis drug candidates. Galapagos and its fee-for-service
subsidiary Fidelta operate with over 1,000 employees in Europe and the US. Follow
Galapagos on Twitter (@GalapagosGlobal) and LinkedIn (Galapagos), or visit our
website at https://www.glpg.com/.
+49 (0)351 7999 2923